Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies (NASDAQ:NTHI) secured a second UAE IND authorization in June 2026, this time for lead intranasal therapy NEO100 in recurrent high-grade gliomas, covering Phase 1–2 adult and pediatric protocols. NEO212 also holds UAE IND status, expanding an international framework that complements U.S. clinical efforts.
NEO100 has FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. Topline Phase 2a NEO100-01 data are expected by end of July 2026. CEO Amir Heshmatpour recently invested over $500,000 in open-market purchases, with insider buying nearing $1 million in a year. NeOnc also cites access to a $75 million ATM facility and a $10 million credit line, alongside growing institutional interest.
NeOnc Technologies (Nasdaq:NTHI) received Department of Health – Abu Dhabi IND approval for NEO100, its intranasal therapy for progressive or recurrent Grade III/IV gliomas. The authorization spans three adult protocols (Phase 1–2) plus a pediatric pathway and complements prior UAE clearance for NEO212.
NEO100 already holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations in the U.S., and the Phase 2a NEO100-01 trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, with top-line data expected by end of July 2026.
NeOnc Technologies (NASDAQ:NTHI) received Abu Dhabi IND authorization for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors, marking its first international clearance.
NEO100’s Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, with tumor remission reported in about 24% of recurrent glioblastoma patients.
CEO Amir Heshmatpour has bought nearly $1 million of stock over the past year. NeOnc also has access to a $75 million ATM facility and a $10 million line of credit.
NeOnc Technologies (Nasdaq:NTHI) received Investigational New Drug (IND) clearance from the Department of Health – Abu Dhabi for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors.
The decision follows completion of Phase 1 dose escalation, which selected 610 mg as the recommended Phase 2 dose and showed encouraging early signs of activity in recurrent glioblastoma and brain metastases. The UAE authorization enables planned Phase 2 development, complements ongoing U.S. FDA discussions on a potential registrational pathway, and marks NEO212’s first international regulatory clearance. NeOnc must still obtain Institutional Review Board approval and update study documents before UAE enrollment, and the clearance does not allow marketing. NeOnc has also applied to DOH Abu Dhabi for its NEO100 programs (NEO100-01, -02, -03) and is awaiting decisions, supporting a multi-program, multi-country CNS oncology strategy based on its NEO platform.
NeOnc Technologies Holdings (NASDAQ:NTHI) is highlighted as part of a new wave of biotech companies operating at the intersection of AI, neuro-oncology, and CNS drug delivery. The discussion focuses on overcoming the blood-brain barrier, improving precision drug delivery for conditions like glioblastoma, and building scalable platform-style therapeutic delivery technologies.
NeOnc Technologies (NASDAQ:NTHI), a clinical-stage CNS oncology company, is drawing increased attention from Wall Street, insiders, and institutions. Maxim Group, Alliance Global Partners, and BTIG Research have initiated coverage with favorable ratings and targets.
CEO Amir Heshmatpour has bought over $500,000 in recent shares, with insider purchases nearing $1 million in a year. Institutional investors such as Bank of America, State Street, and Barclays have raised positions. Lead candidate NEO100 is in a fully enrolled Phase 2a trial for aggressive brain tumors, including glioblastoma, with interim data expected soon. NeOnc is also advancing NEO212, a hybrid CNS therapeutic, leveraging proprietary intranasal delivery designed to bypass the blood-brain barrier.
NeOnc Technologies (Nasdaq:NTHI) reported Q1 2026 results and key clinical milestones. Phase 1 for NEO212 is complete with a 610 mg recommended Phase 2 dose and early signs of possible clinical activity. NEO100 Phase 2a in recurrent IDH1‑mutant high‑grade glioma is fully enrolled, with an interim readout expected around August 2026.
NeOnc raised a PIPE financing anchored by a $10 million Cinctive Capital commitment and had $138,601 in cash at March 31, 2026, plus a $10 million undrawn credit line, which is expected to fund operations into September 2026. Q1 2026 net loss was $8.8 million ($(0.38) per share), including $2.7 million in non‑cash stock‑based compensation, implying non‑GAAP normalized cash operating expenses of about $6.1 million.
NeOnc Technologies (NASDAQ:NTHI) is positioned at the center of a biotech narrative blending insider buying, a Phase 2a brain-cancer program, and a potential delivery-platform advantage. CEO Amir Heshmatpour purchased >$500,000 recently and nearly $1.0M over the past year. The fully enrolled NEO100 trial has interim data expected soon.
NEO100 aims to penetrate the blood-brain barrier for glioblastoma and other CNS indications, which could broaden therapeutic applicability if clinical results are positive.
NeOnc Technology (NASDAQ:NTHI) is a clinical-stage biotech developing intranasal delivery to bypass the blood-brain barrier for CNS cancers. Its lead candidate NEO100 is in a fully enrolled Phase 2a trial for glioblastoma with interim data expected soon. CEO Amir Heshmatpour has bought >$500,000 recently and nearly $1,000,000 over the past year, signaling insider conviction ahead of the clinical catalyst.
Related coverage highlights large insider/strategic buys at other firms, including a ~$1B Volkswagen commitment in Rivian and $4.7M in Sportradar insider purchases.
NeOnc (Nasdaq: NTHI) announced that CEO Amir Heshmatpour has purchased over $500,000 in open-market shares in recent weeks and nearly $1 million over the past year, with additional purchases anticipated. The company completed NEO212 Phase 1 dose escalation and set a recommended Phase 2 dose. The NEO100 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, with an interim analysis expected later in 2026.
All disclosed purchases were made with personal funds and reported on SEC Form 4 filings.